



NDA 8316/S-021

**SUPPLEMENT APPROVAL**

sanofi-aventis U.S. LLC  
Attention: John Cook  
Director, U.S. Regulatory Affairs Marketed Products  
55 Corporate Drive  
Mail Stop 55C-205A  
Bridgewater, NJ 08807

Dear Mr. Cook:

Please refer to your Supplemental New Drug Application (sNDA) dated October 21, 2014, received October 21, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Primaquine (primaquine phosphate) Tablets 26.3 mg.

We acknowledge receipt of your amendments dated February 13, and March 24, 2015.

This “Changes Being Effected” supplemental new drug application provides for revisions to the **PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE** sections to include information regarding the potential for QT interval prolongation. In addition, minor editorial revisions have been made to the **CLINICAL STUDIES** section.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kristine Park, Ph.D., Regulatory Health Project Manager, at (301) 796-0471.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
04/16/2015